Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?
Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-beta (Abeta(42)) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimer's disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the clinical routine and in clinical trials, there is a strong interest in the possible association of Abeta levels in plasma with AD. This review provides an update on the current status of research on plasma Abeta as a biomarker for AD in the context of recent patents in the field.
Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital/Mölndal, S-431 80 Mölndal, Sweden. henrik.zetterberg@gu.se
Henrik
H
Zetterberg
D000544:Alzheimer Disease / Q000097:blood* / Q000134:cerebrospinal fluid / Q000191:economics; D016229:Amyloid beta-Peptides / Q000097:blood* / Q000134:cerebrospinal fluid; D015415:Biomarkers; D003072:Cognition Disorders / Q000097:blood / Q000134:cerebrospinal fluid / Q000209:etiology; D006801:Humans; D010446:Peptide Fragments / Q000097:blood* / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)